Your browser doesn't support javascript.
loading
Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.
Baltschukat, Sabrina; Engstler, Barbara Schacher; Huang, Alan; Hao, Huai-Xiang; Tam, Angela; Wang, Hui Qin; Liang, Jinsheng; DiMare, Matthew T; Bhang, Hyo-Eun Carrie; Wang, Youzhen; Furet, Pascal; Sellers, William R; Hofmann, Francesco; Schoepfer, Joseph; Tiedt, Ralph.
Afiliação
  • Baltschukat S; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland.
  • Engstler BS; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland.
  • Huang A; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts.
  • Hao HX; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts.
  • Tam A; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts.
  • Wang HQ; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts.
  • Liang J; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts.
  • DiMare MT; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts.
  • Bhang HC; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts.
  • Wang Y; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts.
  • Furet P; Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Basel, Switzerland.
  • Sellers WR; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, Massachusetts.
  • Hofmann F; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland.
  • Schoepfer J; Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Basel, Switzerland.
  • Tiedt R; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland. ralph.tiedt@novartis.com.
Clin Cancer Res ; 25(10): 3164-3175, 2019 05 15.
Article em En | MEDLINE | ID: mdl-30674502

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Triazinas / Carcinoma Pulmonar de Células não Pequenas / Proteínas Proto-Oncogênicas c-met / Inibidores de Proteínas Quinases / Avaliação Pré-Clínica de Medicamentos / Imidazóis / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Suíça

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Triazinas / Carcinoma Pulmonar de Células não Pequenas / Proteínas Proto-Oncogênicas c-met / Inibidores de Proteínas Quinases / Avaliação Pré-Clínica de Medicamentos / Imidazóis / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Suíça